2. Academic Validation
  3. Senolytic compounds reduce epigenetic age of blood samples in vitro

Senolytic compounds reduce epigenetic age of blood samples in vitro

  • NPJ Aging. 2025 Feb 4;11(1):6. doi: 10.1038/s41514-025-00199-z.
Vithurithra Tharmapalan 1 2,  Miriam Du Marchie Sarvaas 1 2,  Michael Bleichert 1 2,  Martina Wessiepe 3,  Wolfgang Wagner 4 5 6
Affiliations

Affiliations

  • 1 Institute for Stem Cell Biology, RWTH Aachen University Medical School, 52074, Aachen, Germany.
  • 2 Helmholtz-Institute for Biomedical Engineering, RWTH Aachen University Medical Faculty, 52074, Aachen, Germany.
  • 3 Institute for Transfusion Medicine, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
  • 4 Institute for Stem Cell Biology, RWTH Aachen University Medical School, 52074, Aachen, Germany. wwagner@ukaachen.de.
  • 5 Helmholtz-Institute for Biomedical Engineering, RWTH Aachen University Medical Faculty, 52074, Aachen, Germany. wwagner@ukaachen.de.
  • 6 Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Cologne, Germany. wwagner@ukaachen.de.
PMID: 39905063 DOI: 10.1038/s41514-025-00199-z
Abstract

Senolytic drugs raise the expectation that they can specifically eliminate a subset of senescent cells in a given tissue. In this study, we have exemplarily analyzed if a 3-day treatment of human blood samples in vitro would reduce age-associated biomarkers, with a particular focus on epigenetic age-predictions. Of eight tested compounds, JQ1, RG7112, nutlin-3a, and AMG232 reduced epigenetic age, indicating that this approach may be useful in drug screening for senolytic compounds.

Figures
Products